Indonesia secures $30M Japanese investment for plasma industry

Jakarta (ANTARA) - Japanese biopharmaceutical firm Takeda will invest up to $30 million (approximately Rp539 billion) to develop a plasma-derived medicinal product network in Indonesia, the Ministry of Investment and Downstreaming announced on Tuesday.

The capital injection marks the first phase of a two-year plan aimed at establishing a national plasma bank network to build domestic capacity for the industry.

"This strategic investment goes beyond providing capital by creating opportunities for technology transfer, workforce development, and high-skilled employment," Investment and Downstreaming Minister Rosan Roeslani said in a statement.

Roeslani stated the partnership aligns with government efforts to advance downstreaming policies in strategic sectors, improve public access to essential plasma products, and position the country as a regional hub for healthcare manufacturing.

The first plasma bank under this initiative is scheduled to begin operations by 2027.

Japan remains one of Indonesia's primary foreign investment sources, ranking fifth in the first quarter of 2026 with total investments reaching $1 billion.

Ministry data shows that from 2021 through the first quarter of 2026, total realized Japanese investment reached $18.1 billion, growing at an average annual rate of 13.2% and accounting for nearly 300,000 local jobs.

Translator: Ahmad Muzdaffar, Resinta Sulistiyandari

Editor: Aditya Eko Sigit Wicaksono

Copyright © ANTARA 2026